Sandoz Plans to Invest 50 Million Until 2025 in Its Barcelona Plant

Sandoz begins its journey as an independent company. The pharmaceutical laboratory specializing in off-patent medicines (generic or biosimilars) has announced an investment of fifty million euros until 2025 in the expansion of its plant in Palafolls (Barcelona). The operation is part of the project to strengthen and modernize its antibiotic production network in Europe.

The company ceased to be part of the Novartis structure on October 4th, after its entry as an independent company on the Swiss SIX stock exchange. In this direction, the company has announced that it is strengthening its network of global centers, generating around 150 new additions to the firm’s team. In Madrid, Sandoz has seven of these centers.

Joaquín Rodrigo, president of Sandoz in Spain and general director of the Iberian division, has assured that “our renewed brand reflects our long-standing commitment to innovation in healthcare and our dedication to meeting the global challenge of healthcare,“ according to the manager’s words.

Read more about Sandoz and find the most important financial news of the day with the Born2Invest mobile app.

Sandoz was spun off from Novartis on October 4th, following its listing on the Swiss SIX stock exchange

Specifically, the Sandoz Iberia team plans to make available to professionals and patients a vademecum of more than 200 molecules with more than 600 benefits, among which are one hundred biopatents and eight biosimilars that cover the main therapeutic areas. Secondly, the firm plans to bet, “through transversal collaboration with health agents, on informative attention and the continued training of its professionals.”

Sandoz works with generic or biosimilar medicines with the aim of facilitating patients’ access to health. His portfolio totals more than 1,500 medications and addresses diseases ranging from the common cold to cancer. Based in Basel (Switzerland), its origin dates back to 1886.

After the spin-off of Sandoz, Novartis assured that it could focus its entire strategy on the management of innovative medicines. In addition, the company reaffirmed its forecasts for fiscal year 2023, ensuring that it expected to increase its sales by about 10% and its operating income by between 10% and 15% .

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.